Positive results in three-year trial of Absorb Vascular Scaffold (Abbott)

Three-year results from 101 patients treated with the Absorb Vascular Scaffold (bioresorbable everolimus eluting stent system), from Abbott, in the second stage of the ABSORB trial show that improvements are seen in blood vessel movement and area inside the vessel where the scaffold was placed. Results showed the rate of major adverse cardiovascular events (MACE) in 101 patients was 10 percent at three years, similar to a comparative set of data with a best-in-class drug eluting stent at the same follow-up period. In a subset of 45 patients, state-of-the-art imaging techniques showed improvements in vasomotion (vessel movement) and a 7.2 percent increase in late lumen gain (an increase in the area within the blood vessel) from measurements taken at one and three years.

These findings are unique to Absorb and are not typically observed with metallic stents that cage the vessel. There was also a decrease in plaque area inside the vessel between one and three years. Results were presented at the 62nd Annual Scientific Session of the American College of Cardiology.